In the global competition of iPSC technology, domestic enterprises have demonstrated strong R&D capabilities and market potential. According to incomplete statistics, currently, these 36 domestic enterprises have laid out iPSC-related pipelines.

Recently, according to online public information, Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration issued and announced the first batch of biomedical technology transformation and application project list.

There are 17 mesenchymal stem cell therapeutics approved worldwide, of which 10 are derived from bone marrow, 3 from umbilical cord, 2 from fat, 1 from umbilical cord blood, and 1 from autocorneal limbus.

According to a newly published review by Professor Wang Renzhi's team from the Department of Neurosurgery at Peking Union Medical College Hospital, stem cell therapy is reshaping the treatment landscape of nervous system diseases.

Inventory: Indications, prices, sales

This article reviews the progress in clinical applications of pluripotent stem cell (hPSC)-derived therapies around the world.

On January 7, 2025, China's first induced pluripotent stem cell (iPSC)-derived cell therapy for the treatment of Parkinson's disease made breakthrough progress at Shanghai City Dongfang Hospital.

According to data released by South Korean biotechnology company Medipost in 2024, the cumulative number of patients treated by Cartistem, its knee osteoarthritis stem cell therapy, has exceeded 30000.